PICO Portalanswers from OpenAlex
Innovaderm (Canada)
InstitutionResearch output, impact & collaborations
Innovaderm (Canada) is a institution indexed in PICO Portal from OpenAlex.
What is known about Innovaderm (Canada)?
PICO Portalrecord summary
Innovaderm (Canada) is a research organisation in Montreal, Canada. OpenAlex records 481 works and 24,463 citations for it. 1 researchers list it as their most recent affiliation.
How many works does Innovaderm (Canada) have?
PICO Portalindexed works
Innovaderm (Canada) has 481 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Innovaderm (Canada) have?
PICO Portalcitation count
Innovaderm (Canada) has 24,463 citations in the OpenAlex counts PICO Portal stores.
How many researchers are at Innovaderm (Canada)?
PICO Portalresearcher count
Innovaderm (Canada) has 1 researchers in the PICO Portal index.
What is the average h-index at Innovaderm (Canada)?
PICO Portalavg h-index
Innovaderm (Canada) has an average h-index of 74 in OpenAlex.
What is the ROR of Innovaderm (Canada)?
PICO Portalror
The ROR for Innovaderm (Canada) is on the source record.
What is the OpenAlex record for Innovaderm (Canada)?
PICO Portalopenalex
The OpenAlex for Innovaderm (Canada) is on the source record.
Who are the most-cited researchers behind Innovaderm (Canada)?
PICO Portaltop researchers by citations
What are the most-cited papers on Innovaderm (Canada)?
PICO Portalmost cited works
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Emma Guttman‐Yassky, Robert Bissonnette, Benjamin Ungar, Mayte Suárez‐Fariñas, Marius Ardeleanu, Hitokazu Esaki, Maria Suprun, Yeriel Estrada, Hui Xu, Xiangyu Peng, Jonathan I. Silverberg, Alan Menter, James G. Krueger, Rick Zhang, Usman Chaudhry, Brian N. Swanson, Neil M.H. Graham, Gianluca Pirozzi, George D. Yancopoulos, Jennifer D. Hamilton
Topical tofacitinib for atopic dermatitis: a phase <scp>II</scp> a randomized trial
Robert Bissonnette, Kim Papp, Yves Poulin, Melinda Gooderham, Maitreyi Raman, Lotus Mallbris, C. Wang, Vivek S. Purohit, Carla Mamolo, Jocelyne Papacharalambous, W.C. Ports
Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial
Thomas Ruzicka, Charles Lynde, Gregor B. E. Jemec, Thomas L. Diepgen, J. Berth‐Jones, Pieter‐Jan Coenraads, Andrzej Kaszuba, Robert Bissonnette, E. Varjonen, Péter Holló, F. Cambazard, M. Lahfa, Peter Elsner, Fredrik Nyberg, Åke Svensson, Thomas C. Brown, Martin Harsch, J. Maares
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials
Eric L. Simpson, J.‐P. Lacour, Lynda Spelman, Ricardo Galimberti, Lawrence F. Eichenfield, Robert Bissonnette, Brett King, Jacob P. Thyssen, Jonathan I. Silverberg, Thomas Bieber, Kenji Kabashima, Yuichiro Tsunemi, Antonio Costanzo, Emma Guttman‐Yassky, Lisa A. Beck, Jonathan Janes, Amy M. DeLozier, Margaret Gamalo, Dennis Brinker, T. Cardillo, Fabio P. Nunes, Amy S. Paller, Andreas Wollenberg, Kristian Reich
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon, Kristina Callis Duffin, Robert Bissonnette, Jörg C. Prinz, Yasmine Wasfi, Shu Li, Yaung‐Kaung Shen, Philippe Szapary, B. Randazzo, Kristian Reich
How much of the research on Innovaderm (Canada) is open access?
PICO Portalopen access share
67%OPEN ACCESS